PCM
BMRN icon

Prelude Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Prelude Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-6,100
Closed -$834K – 1489
2015
Q2 		$834K Buy
6,100
+100
+2% +$12.4K 0.12% 207
2015
Q1 		$748K Buy
+6,000
New +$636K 0.1% 238

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Prelude Capital Management's BMRN Position: Q2 2026 in Review

Prelude Capital Management opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 5,799 shares worth $332K. The stake represents 0.02% of the portfolio and ranks #720 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in BMRN as recently as Q3 2025.

Prelude Capital Management first reported a position in BMRN in Q2 2013 and has held it in 36 quarters since. The position peaked at $1.52M in Q4 2022. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Prelude Capital Management held 5,799 shares of BioMarin Pharmaceuticals worth $332K as of Q2 2026.
  • BioMarin Pharmaceuticals was a new Prelude Capital Management position in Q2 2026.
  • BioMarin Pharmaceuticals made up 0.02% of Prelude Capital Management's portfolio in Q2 2026, its #720 holding.
  • Prelude Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 36 quarters since.
  • Prelude Capital Management's BioMarin Pharmaceuticals position peaked at $1.52M in Q4 2022.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.